Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China.

ABSTRACT:

Objective

Telitacicept and belimumab are the only two approved biologics in China for treating systemic lupus erythematosus (SLE). With the widespread clinical use of biologics, more reliable clinical evidence has been provided. This study seeks to evaluate the cost-effectiveness of two biologic treatments for SLE in China by utilizing current medication prices and the most recent clinical research.

Methods

A cost-effectiveness analysis comparing telitacicept and belimumab was conducted by developing a lifetime SLE partition survival model using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) score, which considers the relationship between organ damage and death. The data were extracted from the literature with model assumptions. Scenario analysis o

SUBMITTER: Liu C 

PROVIDER: S-EPMC12852384 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature